Skip to main content

Development of a clinical prediction tool for cancer-associated venous thromboembolism (CAT): the MD Anderson Cancer Center CAT model

Supportive Care in Cancer volume 28, pages 3755–3761 (2020)Cite this article

Abstract

Introduction

Cancer-associated venous thromboembolism (CAT) is a major complication of malignancy. Our goal was to develop a prediction model for VTE that better represented to the population seen at large referral cancer centers.

Materials and methods

This study was nested in a prospective cohort study at the University of Texas MD Anderson Cancer Center that evaluated adult patients during outpatient cancer-staging computed tomography to estimate the prevalence of incidental VTE. Data from patients in whom incidental VTE was not found on initial CT were collected until 24 months ± 7 days from the study inclusion date to determine the occurrence of new VTE events. Demographics, clinical data, current cancer treatment information, and the use of erythropoietin stimulating agents (ESAs) along with hematologic variables were collected in all patients and analyzed to determine differences between those who developed VTE versus those who did not. All candidate variables with significance p value (≤ 0.1) under univariate analysis were considered to enter the final multivariate model.

Results

Data of 548 patients were analyzed. The presence of metastatic disease and the use of platinum-based chemotherapy were strongly associated with CAT occurrence. The use of ESAs and specific malignancies showed trends of association with CAT, while associations were not statistically significant.Those characteristics were utilized to develop a clinical prediction model for CAT readily available and effective (c-index = 0.74).

Conclusion

Our model is effective and easy to incorporate in busy clinical settings and it does not depend on esoteric or difficult-to-obtain laboratory testing. Future external validation studies may provide further evidence for the applicability of our results.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3

Data availability

We have full control of all primary data and we agree to allow the journal to review the data if requested

Abbreviations

CAT:

Cancer-associated venous thromboembolism

VTE:

Venous thromboembolism

CT:

Computed tomography

BMI:

Body mass index

ESA:

Erythropoietin-stimulating agents

Bre:

Breast cancer

Oth:

Other malignancies

GU/Kid:

Cancer of the genitourinary system

Gyn:

Cancer of the gynecologic system

GI/Pan:

Cancer of the gastrointestinal system

References

  1. Wickham N, Gallus AS, Walters BN, Wilson A, Committee NVPGA (2012) Prevention of venous thromboembolism in patients admitted to Australian hospitals: summary of National Health and Medical Research Council clinical practice guideline. Intern Med J 42(6):698–708. https://doi.org/10.1111/j.1445-5994.2012.02808.x

    CAS  Article  PubMed  Google Scholar 

  2. Shen VS, Pollak EW (1980) Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified? South Med J 73(7):841–843

    CAS  Article  Google Scholar 

  3. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158(6):585–593

    CAS  Article  Google Scholar 

  4. Stein PD, Henry JW (1995) Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 108(4):978–981

    CAS  Article  Google Scholar 

  5. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343(25):1846–1850. https://doi.org/10.1056/NEJM200012213432504

    CAS  Article  PubMed  Google Scholar 

  6. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW, American Society of Clinical O (2007) American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25(34):5490–5505. https://doi.org/10.1200/JCO.2007.14.1283

    CAS  Article  PubMed  Google Scholar 

  7. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902–4907. https://doi.org/10.1182/blood-2007-10-116327

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  8. Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R (2012) A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med 7(3):291–292. https://doi.org/10.1007/s11739-012-0784-y

    Article  PubMed  Google Scholar 

  9. Pelzer U, Sinn M, Stieler J, Riess H (2013) Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy? Dtsch Med Wochenschr 138(41):2084–2088. https://doi.org/10.1055/s-0033-1349608

    CAS  Article  PubMed  Google Scholar 

  10. Konigsbrugge O, Pabinger I, Ay C (2014) Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS). Thromb Res 133(Suppl 2):S39–S43. https://doi.org/10.1016/S0049-3848(14)50007-2

    CAS  Article  PubMed  Google Scholar 

  11. Farge D, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana AA, Pabinger I, Solymoss S, Douketis J, Kakkar A (2016) International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancer Oncol 17(10):e452–e466. https://doi.org/10.1016/S1470-2045(16)30369-2

    CAS  Article  Google Scholar 

  12. Cella CA, Di Minno G, Carlomagno C, Arcopinto M, Cerbone AM, Matano E, Tufano A, Lordick F, De Simone B, Muehlberg KS, Bruzzese D, Attademo L, Arturo C, Sodano M, Moretto R, La Fata E, De Placido S (2017) Preventing venous thromboembolism in ambulatory cancer patients: the ONKOTEV study. Oncologist 22(5):601–608. https://doi.org/10.1634/theoncologist.2016-0246

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  13. Pabinger I, van Es N, Heinze G, Posch F, Riedl J, Reitter EM, Di Nisio M, Cesarman-Maus G, Kraaijpoel N, Zielinski CC, Buller HR, Ay C (2018) A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol 5(7):e289–e298. https://doi.org/10.1016/S2352-3026(18)30063-2

    Article  PubMed  Google Scholar 

  14. Escalante CP, Gladish GW, Qiao W, Zalpour A, Assylbekova B, Gao S, Olejeme KA, Richardson MN, Suarez-Almazor ME (2017) Prospective cohort study of cancer patients diagnosed with incidental venous thromboembolism on routine computed tomography scans. Support Care Cancer 25(5):1571–1577. https://doi.org/10.1007/s00520-016-3559-6

    Article  PubMed  Google Scholar 

  15. Lubsen J, Pool J, van der Does E (1978) A practical device for the application of a diagnostic or prognostic function. Methods Inf Med 17(2):127–129

    CAS  Article  Google Scholar 

  16. J B (1985) Nomograms. In: S K, NL J (eds) Encyclopedia of Statistical Sciences, vol 6. Wiley, New York,

  17. Cronin KA, Lake AJ, Scott S, Sherman RL, Noone AM, Howlader N, Henley SJ, Anderson RN, Firth AU, Ma J, Kohler BA, Jemal A (2018) Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cancer 124(13):2785–2800. https://doi.org/10.1002/cncr.31551

    Article  PubMed  PubMed Central  Google Scholar 

  18. Zhan P, Wang Q, Qian Q, Yu LK (2012) Risk of venous thromboembolism with the erythropoiesis-stimulating agents (ESAs) for the treatment of cancer-associated anemia: a meta-analysis of randomized control trials. Chin Clin Oncol 1(2):19. https://doi.org/10.3978/j.issn.2304-3865.2012.12.10

    Article  PubMed  Google Scholar 

  19. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Francis CW, Gates LE, Kakkar AK, Levine MN, Liebman HA, Tempero MA, Lyman GH, Falanga A (2019) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol:JCO1901461. doi:https://doi.org/10.1200/JCO.19.01461

  20. Khorana AA, Francis CW, Culakova E, Lyman GH (2005) Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 104(12):2822–2829. https://doi.org/10.1002/cncr.21496

    Article  PubMed  Google Scholar 

  21. van Es N, Di Nisio M, Cesarman G, Kleinjan A, Otten HM, Mahe I, Wilts IT, Twint DC, Porreca E, Arrieta O, Stepanian A, Smit K, De Tursi M, Bleker SM, Bossuyt PM, Nieuwland R, Kamphuisen PW, Buller HR (2017) Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica 102(9):1494–1501. https://doi.org/10.3324/haematol.2017.169060

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  22. Wolfson JA, Sun CL, Wyatt LP, Hurria A, Bhatia S (2015) Impact of care at comprehensive cancer centers on outcome: results from a population-based study. Cancer 121(21):3885–3893. https://doi.org/10.1002/cncr.29576

    Article  PubMed  PubMed Central  Google Scholar 

  23. Louzada ML, Majeed H, Dao V, Wells PS (2011) Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-associated thrombosis: a systematic review of observational and intervention studies. Blood Coagul Fibrinolysis 22(2):86–91. https://doi.org/10.1097/MBC.0b013e328341f030

    CAS  Article  PubMed  Google Scholar 

  24. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M, Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer I (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146–153. https://doi.org/10.1056/NEJMoa025313

    CAS  Article  PubMed  Google Scholar 

  25. Lee AY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA, Investigators C (2015) Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. Jama 314(7):677–686. https://doi.org/10.1001/jama.2015.9243

    CAS  Article  PubMed  Google Scholar 

  26. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, Buller HR, Hokusai VTECI (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378(7):615–624. https://doi.org/10.1056/NEJMoa1711948

    CAS  Article  PubMed  Google Scholar 

  27. Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, Hale D, Dunn JA, Lyman GH, Hutchinson C, MacCallum P, Kakkar A, Hobbs FDR, Petrou S, Dale J, Poole CJ, Maraveyas A, Levine M (2018) Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 36(20):2017–2023. https://doi.org/10.1200/JCO.2018.78.8034

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Section of Benign Hematology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1464, Houston, TX, USA

    Cristhiam M. Rojas-Hernandez

  2. Department of Pulmonary Disease and Critical Care Medicine, The University of Texas, McGovern Medical School, Houston, TX, USA

    Victoria K. Tang

  3. Department of Medical Oncology and Hematology, The University of Maryland, Baltimore, MD, USA

    Gabriela Sanchez-Petitto

  4. Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

    Wei Qiao

  5. Department of Internal Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

    Marsha Richardson

  6. Department of Internal Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

    Carmen Escalante

Authors
  1. Cristhiam M. Rojas-Hernandez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Victoria K. Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gabriela Sanchez-Petitto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei Qiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marsha Richardson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Carmen Escalante
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cristhiam M. Rojas-Hernandez.

Ethics declarations

The study was approved by The University of Texas MD Anderson Cancer Center Institutional Review Board.

Conflict of interest

Dr. Rojas-Hernandez has received research funding from Daichii Sankyo pharmaceuticals not related to the content of the present manuscript. The other authors have no conflicts of interest to declare.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Preliminary data of this study have been presented during poster sessions at the International Society of Thrombosis of Haemostasis-2017 and the American Society of Hematology-2017.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Rojas-Hernandez, C.M., Tang, V.K., Sanchez-Petitto, G. et al. Development of a clinical prediction tool for cancer-associated venous thromboembolism (CAT): the MD Anderson Cancer Center CAT model. Support Care Cancer 28, 3755–3761 (2020). https://doi.org/10.1007/s00520-019-05150-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-019-05150-z

Keywords

  • Thrombosis
  • Cancer
  • Score
  • Prediction
  • Metastasis
  • Chemotherapy